Insights

Top broker still sees value in the Pro Medicus (ASX:PME) share price

One leading broker believes this high-flying ASX share can continue to soar…
The post Top broker still sees value in the Pro Medicus (ASX:PME) share price appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price was on form on Thursday.

The health imaging company’s shares rose over 3% to $47.61.

This means the Pro Medicus share price is now up almost 36% since the start of the year.

Why did the Pro Medicus share price storm higher?

Investors were bidding the Pro Medicus share price higher on Thursday after the company announced a deal with healthcare giant Mayo Clinic.

According to the release, the company’s Visage Imaging business has signed a multi-year research collaboration agreement with Mayo Clinic that will facilitate development and commercialisation activities in the field of artificial intelligence (AI), leveraging the Visage AI Accelerator platform.

Can its shares go higher?

According to a note out of Goldman Sachs, its analysts still see value in Pro Medicus’ shares.

This morning the broker has retained its buy rating and $53.80 price target on the company’s shares. Based on the latest Pro Medicus share price, this implies potential upside of 13% over the next 12 months.

Goldman commented: “PME today announced that it has signed a multi-year research collaboration with Mayo Clinic, one of the leading academic healthcare networks in the US. This agreement will facilitate the two parties’ research efforts around Artificial Intelligence in the field of radiology, with the primary aim of developing/commercialising new products.”

“Following today’s announcement, we highlight that PME has now established R&D collaborations with three different, world-renowned healthcare networks. These efforts have already yielded an interesting commercial opportunity, which could provide a material revenue contribution from FY22. We believe the strategy of partnering with the leading academics helps to maximise the value and competitive advantage of PME’s technology proposition,” the broker commented.

In light of the above, this could make it worth considering Pro Medicus at the current level.

The post Top broker still sees value in the Pro Medicus (ASX:PME) share price appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!